Aortic & peripheral vascular disease
Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis
Authors' conclusion
DCB endovascular therapy is a reasonable treatment for femoropopliteal lesions in patients on HD.
Study context
- Population
- Patients undergoing DCB (Lutonix or IN.PACT Admiral) for symptomatic femoropopliteal artery disease, March 2018 to December 2019
- Participants
- 3,165 lesions
- Exposure
- Hemodialysis (HD) vs non-HD after femoropopliteal DCB therapy
- HDn = 991 lesions
- non-HDn = 2,174 lesionsreference
- Outcome
- Freedom from restenosis
Methodological detailspropensity-score matched
- Propensity-score matched
Main finding
As reported in the abstract
1 year
| Group | Value | 3-year freedom from restenosis |
|---|---|---|
| HD | 82.2% (95% CI 79.0%–85.3%) | 61.9% (57.7%-66.1%) |
| non-HD | 85.8% (95% CI 83.0%–88.7%) | 66.3% (62.2%-70.4%) |
Value
HD82.2% (95% CI 79.0%–85.3%)
non-HD85.8% (95% CI 83.0%–88.7%)
3-year freedom from restenosis
HD61.9% (57.7%-66.1%)
non-HD66.3% (62.2%-70.4%)
Observational data: associations, not effects.
Further findings
- Restenosis in HD · median follow-up 16.2 months (Q1-Q3: 7.2-35.5 months)
- 363 · events
Restenosis in HD · median follow-up 16.2 months (Q1-Q3: 7.2-35.5 months)
- Independent risk factors in HD: no below-the-knee runoff, prior endovascular therapy, popliteal lesion, severe calcification, Lutonix use, severe dissection
Original publication
Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis. JACC Cardiovasc Interv. Published 14 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it